cilostazol has been researched along with Cerebrovascular Moyamoya Disease in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease." | 3.01 | Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions. ( Abedi, A; Choi, W; Nguyen, VN; Rennert, RC; Russin, JJ; Sizdahkhani, S, 2023) |
| "Adult patients with ischemic moyamoya disease (MMD) who receive treatment with antiplatelet drugs reportedly show improvements in neuropsychological test scores after around 2 years." | 1.51 | Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort. ( Ando, S; Chiba, T; Fujiwara, S; Kobayashi, M; Kubo, Y; Miyoshi, K; Ogasawara, K; Sato, S; Setta, K; Tsutsui, S; Yanagihara, W; Yoshida, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abedi, A | 1 |
| Sizdahkhani, S | 1 |
| Choi, W | 1 |
| Nguyen, VN | 1 |
| Rennert, RC | 1 |
| Russin, JJ | 1 |
| Seo, WK | 1 |
| Kim, JY | 1 |
| Choi, EH | 1 |
| Kim, YS | 1 |
| Chung, JW | 1 |
| Saver, JL | 1 |
| Bang, OY | 1 |
| Kim, GM | 1 |
| Chiba, T | 2 |
| Setta, K | 2 |
| Shimada, Y | 1 |
| Yoshida, J | 1 |
| Fujimoto, K | 1 |
| Tsutsui, S | 2 |
| Yoshida, K | 2 |
| Kobayashi, M | 2 |
| Kubo, Y | 2 |
| Fujiwara, S | 2 |
| Terasaki, K | 1 |
| Ogasawara, K | 2 |
| Ando, S | 1 |
| Miyoshi, K | 1 |
| Sato, S | 1 |
| Yanagihara, W | 1 |
1 review available for cilostazol and Cerebrovascular Moyamoya Disease
| Article | Year |
|---|---|
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions.
Topics: Cerebral Revascularization; Cilostazol; Humans; Moyamoya Disease; Platelet Aggregation Inhibitors; S | 2023 |
3 other studies available for cilostazol and Cerebrovascular Moyamoya Disease
| Article | Year |
|---|---|
Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study.
Topics: Adult; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Moyamoya Disease; Platelet | 2021 |
Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort.
Topics: Adult; Blood Flow Velocity; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Dr | 2018 |
Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort.
Topics: Adult; Cilostazol; Clopidogrel; Cognition; Female; Follow-Up Studies; Humans; Male; Middle Aged; Moy | 2019 |